Drug Profile
Veglin
Alternative Names: VEGF antisense oligonucleotide - VasGene Therapeutics; VEGF-ASLatest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals; University of Southern California; VasGene Therapeutics
- Developer VasGene Therapeutics
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Kaposi's sarcoma; Mesothelioma; Renal cancer